Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Interpatient variation in normal peripheral zone apparent diffusion coefficient: effect on the prediction of prostate cancer aggressiveness.

Litjens GJ, Hambrock T, Hulsbergen-van de Kaa C, Barentsz JO, Huisman HJ.

Radiology. 2012 Oct;265(1):260-6. Epub 2012 Aug 24.

PMID:
22923722
2.

Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer.

Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA, Scheenen T, Barentsz JO.

Radiology. 2011 May;259(2):453-61. doi: 10.1148/radiol.11091409.

PMID:
21502392
3.

Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness.

Vargas HA, Akin O, Franiel T, Mazaheri Y, Zheng J, Moskowitz C, Udo K, Eastham J, Hricak H.

Radiology. 2011 Jun;259(3):775-84. doi: 10.1148/radiol.11102066. Epub 2011 Mar 24.

4.

Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer.

Rosenkrantz AB, Sigmund EE, Johnson G, Babb JS, Mussi TC, Melamed J, Taneja SS, Lee VS, Jensen JH.

Radiology. 2012 Jul;264(1):126-35. doi: 10.1148/radiol.12112290. Epub 2012 May 1.

PMID:
22550312
5.

Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient.

Donati OF, Mazaheri Y, Afaq A, Vargas HA, Zheng J, Moskowitz CS, Hricak H, Akin O.

Radiology. 2014 Apr;271(1):143-52. doi: 10.1148/radiol.13130973. Epub 2013 Dec 12. Erratum in: Radiology. 2014 Oct;273(1):311.

PMID:
24475824
6.

Evaluation of the normal-to-diseased apparent diffusion coefficient ratio as an indicator of prostate cancer aggressiveness.

Lebovici A, Sfrangeu SA, Feier D, Caraiani C, Lucan C, Suciu M, Elec F, Iacob G, Buruian M.

BMC Med Imaging. 2014 May 10;14:15. doi: 10.1186/1471-2342-14-15.

7.

Transition zone prostate cancer: incremental value of diffusion-weighted endorectal MR imaging in tumor detection and assessment of aggressiveness.

Jung SI, Donati OF, Vargas HA, Goldman D, Hricak H, Akin O.

Radiology. 2013 Nov;269(2):493-503. doi: 10.1148/radiol.13130029. Epub 2013 Jul 22.

PMID:
23878284
8.

Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings.

Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J, Inurrigarro G, Moskowitz CS, Ishill NM, Reuter VE, Touijer K, Zakian KL, Koutcher JA.

Radiology. 2008 Feb;246(2):480-8. doi: 10.1148/radiol.2462070368.

PMID:
18227542
9.

Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T.

Nagel KN, Schouten MG, Hambrock T, Litjens GJ, Hoeks CM, ten Haken B, Barentsz JO, Fütterer JJ.

Radiology. 2013 Apr;267(1):164-72. doi: 10.1148/radiol.12111683. Epub 2013 Jan 17.

PMID:
23329653
10.

Reducing the influence of b-value selection on diffusion-weighted imaging of the prostate: evaluation of a revised monoexponential model within a clinical setting.

Mazaheri Y, Vargas HA, Akin O, Goldman DA, Hricak H.

J Magn Reson Imaging. 2012 Mar;35(3):660-8. doi: 10.1002/jmri.22888. Epub 2011 Nov 8. Erratum in: J Magn Reson Imaging. 2012 Nov;36(5):1256.

11.

Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers.

Langer DL, van der Kwast TH, Evans AJ, Sun L, Yaffe MJ, Trachtenberg J, Haider MA.

Radiology. 2008 Dec;249(3):900-8. doi: 10.1148/radiol.2493080236.

PMID:
19011187
12.

Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis.

Tamada T, Sone T, Jo Y, Yamamoto A, Yamashita T, Egashira N, Imai S, Fukunaga M.

Radiology. 2008 Aug;248(2):531-9. doi: 10.1148/radiol.2482070157. Epub 2008 Jun 6.

PMID:
18539890
13.

Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?

Turkbey B, Shah VP, Pang Y, Bernardo M, Xu S, Kruecker J, Locklin J, Baccala AA Jr, Rastinehad AR, Merino MJ, Shih JH, Wood BJ, Pinto PA, Choyke PL.

Radiology. 2011 Feb;258(2):488-95. doi: 10.1148/radiol.10100667. Epub 2010 Dec 21.

15.

Diffusion tensor magnetic resonance imaging of prostate cancer.

Manenti G, Carlani M, Mancino S, Colangelo V, Di Roma M, Squillaci E, Simonetti G.

Invest Radiol. 2007 Jun;42(6):412-9.

PMID:
17507813
16.
17.

Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T.

Kobus T, Vos PC, Hambrock T, De Rooij M, Hulsbergen-Van de Kaa CA, Barentsz JO, Heerschap A, Scheenen TW.

Radiology. 2012 Nov;265(2):457-67. doi: 10.1148/radiol.12111744. Epub 2012 Jul 27.

PMID:
22843767
18.

Clinical applications of diffusion-weighted-MRI in prostate cancer.

Wibulpolprasert P, Phongkitkarun S, Chalermsanyakorn P.

J Med Assoc Thai. 2013 Aug;96(8):967-75.

PMID:
23991605
19.

Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason Grades than TRUS-guided biopsies in peripheral zone tumours.

Bittencourt LK, Barentsz JO, de Miranda LC, Gasparetto EL.

Eur Radiol. 2012 Feb;22(2):468-75. doi: 10.1007/s00330-011-2269-1. Epub 2011 Sep 14.

PMID:
21913058
20.

Clinical utility of apparent diffusion coefficient values obtained using high b-value when diagnosing prostate cancer using 3 tesla MRI: comparison between ultra-high b-value (2000 s/mm²) and standard high b-value (1000 s/mm²).

Kitajima K, Takahashi S, Ueno Y, Yoshikawa T, Ohno Y, Obara M, Miyake H, Fujisawa M, Sugimura K.

J Magn Reson Imaging. 2012 Jul;36(1):198-205. doi: 10.1002/jmri.23627. Epub 2012 Feb 27.

PMID:
22371381

Supplemental Content

Support Center